For Illumina, its former employees are both a boon and a problem. In the 27 years since its founding, the DNA sequencing ...

Oric Pharmaceuticals raises $125M for Phase 3 prostate cancer drug ORIC-944 after positive early results, with study planned ...

After a slight delay, the FDA rejected Stealth BioTherapeutics' Barth syndrome drug application for elamipretide, but will ...

EDO51 for Duchenne muscular dystrophy after Phase 2 trial failure, abandons three preclinical programs, and pivots to focus ...

Since Bernard Ravina's medical training in neurology in the '90s, there have been few new therapies that treat a movement ...

Post-Hoc Live to discuss John Carroll's Endpoints 100 survey on biopharma industry sentiment, featuring Kyle LaHucik, ...

Novo Nordisk warned the US government not to impose pharma-specific tariffs, but instead to tax illegal importers of ...

The US’ stance on Covid-19 vaccines under HHS chief Robert F. Kennedy Jr. is coming into focus with a new approval framework, ...

Devoted Health, the Medicare Advantage insurer with a medical group, has laid off about 120 employees. The layoffs, which ...

GSK and Spero Therapeutics announced that a Phase 3 trial for their complicated UTI antibiotic reached its primary endpoint, ...

TIGIT drug collaboration. Company will wind down operations and sell assets, including EOS-984 and EOS-215 programs.

Compass awaits Phase 3 COMP360 trial results for treatment-resistant depression amid renewed optimism for psychedelics.